# Safety of Fentanyl TAIFUN Treatment

> **NCT00822614** · PHASE3 · UNKNOWN · sponsor: **Akela Pharma, Inc.** · enrollment: 500 (estimated)

## Conditions studied

- Breakthrough Cancer Pain

## Interventions

- **DRUG:** Fentanyl TAIFUN
- **DRUG:** Opioid

## Key facts

- **NCT ID:** NCT00822614
- **Lead sponsor:** Akela Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2008-12
- **Primary completion:** 2009-12
- **Final completion:** 2010-01
- **Target enrollment:** 500 (ESTIMATED)
- **Last updated:** 2009-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00822614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00822614, "Safety of Fentanyl TAIFUN Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00822614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*